TotalMarketCap

Exelixis

EXELNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$16.762 B

$68.70 -5.57%

Close of 6 Nov 2026

As of 6 Nov 2026, Exelixis (EXEL) has a market capitalization of $16.8B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$2.32B

#1051 by revenue

Earnings

$782.6M

#468 by earnings

Shares outstanding

244,010,895

Latest filing cover page

P/E ratio

21.4

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #6BiogenBIIB$36.1B
  2. #7BioNTech SEBNTX$21.6B
  3. #8ExelixisEXEL$16.8B
  4. #9Neurocrine BiosciencesNBIX$16.2B
  5. #10Halozyme TherapeuticsHALO$14.0B

What if Exelixis were worth as much as…

Open the what-if tool →

Gold $28.2T

$115,719.73

Per share 1,685× higher

Bitcoin $1.53T

$6,261.39

Per share 91.1× higher

Apple $5.02T

$20,555.57

Per share 299× higher

Or at a round number

$50.0B$100.0B$200.0B$500.0B

Where these numbers come from

Share counts and financials for Exelixis are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.